Options for the development of a bivalent vaccine against SARS-CoV-2 and influenza

Ekaterina StepanovaDepartment of Virology, Institute of Experimental Medicine, Saint Petersburg, RussiaView further author information

Irina Isakova-SivakDepartment of Virology, Institute of Experimental Medicine, Saint Petersburg, Russia

https://orcid.org/0000-0002-2801-1508 View further author information

Larisa RudenkoDepartment of Virology, Institute of Experimental Medicine, Saint Petersburg, RussiaCorrespondence[email protected]
View further author information

Click to increase image sizeClick to decrease image size

Declaration of interest

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or material discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or mending, or royalties.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Additional information

Funding

This work was supported by the Russian Science Foundation under Grant [21-75-30003].

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Options for the development of a bivalent vaccine against SARS-CoV-2 and influenza

Information for

Open access

Opportunities

Help and information

Options for the development of a bivalent vaccine against SARS-CoV-2 and influenza

Declaration of interest

Reviewer disclosures

Additional information

Funding

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature